Veröffentlichungen

Artikel

Sollte einer der verlinkten Artikel nicht im Volltext für Sie erreichbar sein (bspw. weil dieser nur mit einem Abonnement verfügbar ist) sprechen Sie uns gerne an.

Bitte beachten Sie auch die weiteren Arten von Veröffentlichungen (Poster / Vorträge / Broschüren / Grafiken des Quartals / Berichte)

Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry

Frahm N, Ellenberger D et al., 2024: Therapeutic Advances in Neurological Disorders 
first published online: March 29, 2024 ; doi: 10.1177/17562864241239740

 

Disease-modifying therapy initiation patterns in multiple sclerosis in three large MS populations

Stahmann A, Craig E, Ellenberger D et al., 2024: Therapeutic Advances in Neurological Disorders 
first published online: March 15, 2024 ; doi: 10.1177/17562864241233044

 

Persons with multiple sclerosis older than 55 years: an analysis from the German MS registry

Goereci Y, Ellenberger D, Rommer P et al., 2024: Journal of Neurology
first published online: March 22, 2024 ; doi: 10.1007/s00415-024-12286-4

 

Introducing a core dataset for real-world data in multiple sclerosis registries and cohorts: Recommendations from a global task force

Parciak T, Geys L et al., 2023: Multiple Sclerosis Journal
first published online: December 23, 2023 ; doi: 10.1177/13524585231216004

 

Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis

Abdelhak A, Antweiler K et al., 2023: Annals of Clinical and Translational Neurology 
first published online: December 19, 2023 ; doi: 10.1002/acn3.51969

 

Occurrence and Risk Factors of Relapse Activity after Vaccination against COVID-19 in People with Multiple Sclerosis: 1-Year Follow-Up Results from a Nationwide Longitudinal Observational Study

Fneish F, Frahm N et al., 2023: Vaccines       
first published online: December 16, 2023 ; doi: 10.3390/vaccines11121859

 

Patient-reported Outcome Parameters and Disability Worsening in Progressive Multiple Sclerosis

Abdelhak A, Antweiler K et al., 2023: Multiple Sclerosis and Related Disorders      
first published online: November 17, 2023; doi: 10.1016/j.msard.2023.105139

 

Epileptic seizures at multiple sclerosis onset and their role in disease progression

Grothe M, Ellenberger D, Zettl U K et al., 2023: Therapeutic Advances in Neurological Disorders      
first published online: October 6, 2023; doi: 10.1177/17562864231192826

 

The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across Europe

Nicholas R, Rodgers J et al., 2023: Therapeutic Advances in Neurological Disorders     
first published online: September 26, 2023; doi: 10.1177/17562864231198963

 

Mit Daten die Versorgung verbessern: Wofür gibt es eigentlich das MS-Register?

Veröffentlicht: Juli 2023 in Neurovision. Neurologie verstehen. Jahrgang 18, Ausgabe 2, S. 16 f., Type: Adobe/PDF

Application of Statistical Methods for Central Statistical Monitoring and Implementations on the German Multiple Sclerosis Registry

Fneish F, Ellenberger D, Frahm N et al. 2023: Therapeutic Innovation & Regulatory Science
published online: 14 July 2023; doi: 10.1007/s43441-023-00550-0

 

Frequency and Predictors of Relapses following SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis: Interim Results from a Longitudinal Observational Study

Frahm N, Fneish F, et al., 2023: Journal of Clinical Medicine, Vol. 12, Issue 11,
published online: 24 May 2023; doi: 10.3390/jcm12113640

 

Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers

Forsberg L, Spelman T et al on behalf of the SPMS Research Collaboration Network 2023: Multiple Sclerosis Journal – Experimental, Translational and Clinical, Volume 9, Issue 1; published online: February 16, 2023; doi: 10.1177/20552173231153557

Adverse events in MS patients fulfilling or not inclusion criteria of the respective clinical trial – the problem of generalizability

Jalusic KO, Ellenberger D, Stahmann A, Berger K on behalf for the REGIMS Investigators, 2022:
Multiple Sclerosis and Related Disorders, published online: 19 November 2022; doi: 10.1016/j.msard.2022.104422

Updated Results of the COVID-19 in MS Global Data Sharing Initiative:
Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity

Simpson-Yap S, Stahmann A, et al., 2022: Neurology: Neuroimmunology & Neuroinflammation, Vol. 9 Issue 6,
published online: 29 August 2022; doi: 10.1212/NXI.0000000000200021

SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational study

Frahm, N et al., 2022: The Lancet Regional Health - Europe, Vol. 22, published online: 2 September 2022; 
doi: 10.1016/j.lanepe.2022.100502

Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β

Simson-Yap, S et al., 2022: Multiple Sclerosis and Related Disorders, Vol. 66; published online: July 25, 2022; doi:10.1016/j.msard.2022.104072

Comparison of employment among people with Multiple Sclerosis across Europe

Ellenberger D, Parciak T, Brola W, Hillert J, Middleton R, Stahmann A, Thalheim C, Flachenecker P, 2021: MSJ-ETC Article first published online: April 27, 2022, doi:10.1177/20552173221090653

Trends in administrative prevalence of multiple sclerosis and utilization patterns of disease modifying drugs in Germany

Holstiege J, Akmatov MK, Klimke K, Dammertz L, Kohring C, Marx C, Frahm N, Peters M, Ellenberger D, Zettl UK, Rommer PS, Stahmann A, Bätzing J; 2022: Multiple Sclerosis and Related Disorders published online: January 21, 2022; doi:10.1016/j.msard.2022.103534

Communication, Coordination, and Security for People with Multiple Sclerosis (COCOS-MS): a randomised phase II clinical trial protocol

Golla H, Dillen K, Warnke C, et al., 2022: BMJ Open article first published: 25 January 2022; doi:10.1136/bmjopen-2021-049300

Therapy Switches in Fingolimod-Treated Patients with Multiple Sclerosis: Long-Term Experience from the German MS Registry

Frahm N, Fneish F, Ellenberger D, et al., 2022: Neurology and Therapy article published online: 12 January 2022; doi:10.1007/s40120-021-00320-w

How is and how should healthcare for people with multiple sclerosis in Germany be designed?–The rationale and protocol for the mixed-methods study Multiple Sclerosis–Patient-Oriented Care in Lower Saxony (MS-PoV)

Krüger K, Fricke LM, Stahmann A, et al., 2021: PLOS ONE published: November 11, 2021; doi:10.1371/journal.pone.0259855

Treatment patterns in pediatric patients with multiple sclerosis in Germany—a nationwide claim-based analysis

Frahm N, Peters M, Bätzing J, Ellenberger D, Akmatov MK, Haas J, Rommer PS, Stahmann A, Zettl UK, Holstiege J, 2021: Therapeutic Advances in Neurological Disorders published online: October 6, 2021; doi:10.1177/17562864211048336

Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis

Simpson-Yap S, Stahmann A, et al., 2021: Neurology Article first published online: October 5, 2021; doi:10.1212/WNL.0000000000012753

Epilepsy as a predictor of disease progression in multiple sclerosis

Grothe M, Ellenberger D, von Podewils F, Stahmann A, Rommer PS, Zettl UK, 2021: MSJ Article first published online: October 1, 2021, doi:10.1177/13524585211046739

Characteristics of secondary progressive multiple sclerosis: Disease activity and provision of care in Germany – a registry-based/multicentric cohort study

Frahm N, Ellenberger D, Fneish F, Kleinschnitz C, Warnke C, Zettl UK, Friedemann P, Rauser B, Stahmann A, Vogelmann V, Flachenecker P; 2021: Multiple Sclerosis and Related Disorders published online: September 26, 2021; doi:10.1016/j.msard.2020.102634

Time to diagnosis in multiple sclerosis: Epidemiological data from the German Multiple Sclerosis Registry

Blaschke SJ, Ellenberger D, Flachenecker P, Hellwig K, Paul F, Pöhlau D, Kleinschnitz C, Rommer PS, Rueger MA, Zettl UK, Stahmann A, Warnke C, 2021: MSJ Article first published online: August 27, 2021, doi:10.1177/13524585211039753

Prevalence of pediatric multiple sclerosis in Germany - a nationwide population-based analysis

Frahm N, Peters M, Bätzing J, Ellenberger D, Akmatov MK, Haas J, Rommer PS, Stahmann A, Zettl UK, Holstiege J, 2021: European Journal of Neurology Vol 28, Issue 9, p3173-3176, first published online: July 9, 2021 doi:10.1111/ene.15015

Chances and challenges of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registry

Ohle LM, Ellenberger D, Flachenecker P, Friede T, Haas J, Hellwig K, Parciak T, Paul F, Warnke C, Stahmann A, 2021: Scientific Reports, Vol. 11, Article number: 13340 (2021); published online: June 25, 2021 doi:10.1038/s41598-021-92722-x

Effect of applying inclusion and exclusion criteria of phase III clinical trials to multiple sclerosis patients in routine clinical care

Jalusic K, Stahmann A, et. al, 2021: MSJ Article first published online: January 20, 2021; doi:10.1177/1352458520985118

Multiple Sclerosis Data Alliance – A global multi-stakeholder collaboration to scale-up real world data research

Peeters, L et al.; 2021: Multiple Sclerosis and Related Disorders, Vol. 47 : Januar 2021; doi:10.1016/j.msard.2020.102634

Aggressive multiple sclerosis – a matter of measurement and timing

Ellenberger D, Flachenecker P, Fneish F, Frahm N,Hellwig K, Paul F, Stahmann A, Warnke C, Rommer PS, Zettl UK; 2020: BRAIN published online: September 2020; doi:10.1093/brain/awaa306
 

Relapsing and progressive MS: the sex-specific perspective

Rommer PS, Ellenberger D, Hellwig K, Haas J, Pöhlau D, Stahmann A, Zettl UK, on behalf of the Scientific Advisory Group of the German MS-Register by the German MS Society, 2020: Therapeutic Advances in Neurological Disorders published online: September 2020; doi:10.1177/1756286420956495

Is benign MS really benign? What a meaningful classification beyond the EDSS must take into consideration

Ellenberger D, Flachenecker P, Haas J, Hellwig K, Paul F, Stahmann A, Warnke C, Zettl UK, Rommer PS, 2020: Multiple Sclerosis and Related Disorders published online: September 2020; doi:10.1016/j.msard.2020.102485

Management of MS patients treated with daclizumab - a case series of 267 patients

Rommer PS, Berger K, Ellenberger D, Fneish F, Simbrich A, Stahmann A, Zettl K, 2020: Frontiers in Neurology published online: July 29, 2020; doi:10.3389/fneur.2020.00996

COVID-19 in people with multiple sclerosis: A global data sharing initiative

Peeters L, Stahmann A, et. al, 2020: MSJ Article first published online: July 14, 2020; doi:10.1177/1352458520941485

Explorative Study of Emerging Blood Biomarkers in Progressive Multiple Sclerosis (EmBioProMS): Design of a Prospective Observational Multicentre Pilot Study

A Abdelhak, A Huss, A Stahmann, M Senel, M Krumbholz, M C Kowarik, J Havla, et al, 2020: Contemporary Clinical Trials Communications, May 19, 2020, doi: 10.1016/j.conctc.2020.100574 

Data harmonization for collaborative research among MS registries: A case study in employment

Salter, A, Stahmann, A, Ellenberger, D et. al, 2020: MSJ Article first published online: March 12, 2020; doi:10.1177/1352458520910499

 

Multiple sclerosis registries in Europe – an updated mapping survey

Glaser et. al, 2018: Multiple Sclerosis and Related Disorders, doi:10.1016/j.msard.2018.09.032 , Volume  27 (2019), S. 171–178 published online ahead of print
 

Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry

Rommer et. al, 2018 (published online ahead of print): Multiple Sclerosis Journal, Volume 25, Issue 12, 1641-1652, doi: 10.1177/1352458518799580,

Decreasing longitudinal use of glucocorticosteroids in multiple sclerosis

Ellenberger et al, 2018: Multiple Sclerosis and Related Disorders, doi: 10.1016/j.msard.2018.07.040, Volume 25, 173-174
 

MS in Deutschland: Symptome und Behandlungsdefizite

Zettl et al, 2018: Neurotransmitter, doi:10.1007/s15016-018-6423-8, Volume 29 [Issue 6] S. 42-44
 

Neuroimmunologische Register in Deutschland

Thiel et. al, 2018: Akt Neurol 2018; 45(01): 7-23 doi:10.1055/s-0043-108909, Type: http/URL
 

„Symptomatic treatment in multiple sclerosis—interim analysis of a nationwide registry“

Veröffentlicht: 9. Juni 2016 (online), in Acta Neurologica Scandinavica, doi:10.1111/ane.12612, Volume 135 [Issue 4] S.394-399 (April 2017), Type: http/URL
 

„Patients characteristics influencing the longitudinal utilization of steroids in multiple sclerosis – an observational study“

Veröffentlicht: 9. Mai 2015 (online), in European Journal of Clinical Investigation, doi:10.1111/eci.12450, Volume 45 [Issue 6] S.587-593 (Juni 2015), Type: http/URL
 

Entwicklung einer App für die Integration von PRO-Daten in das nationale MS-Register – Zwischenergebnisse einer Machbarkeitsstudie

Veröffentlicht: September 2014, GMDS 2014: 59. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie e.V. (GMDS), Göttingen, doi: 10.3205/14gmds234 Type: http/URL
 

„Multiple Sclerosis Registries in Europe – Results of a Systematic Survey“.

Veröffentlicht: 28. April 2014 (online), in Multiple Sclerosis Journal, doi:10.1177/1352458514528760, Volume 20 [Issue 11] S.1523-1532 (Oktober 2014), Type: http/URL
 

Assess, compare and enhance the status of Persons with Multiple Sclerosis (MS) in Europe

Veröffentlicht: Dezember 2012 in Acta Neurologica Scandinavica, Volume 126 [Issue s195] S.24–30, doi:10.1111/ane.12024, Type: http/URL
 

Making EUReMS count for people with multiple sclerosis

Veröffentlicht: Oktober 2011 in The Lancet Neurology - Editorial, doi:10.1016/S1474-4422(11)70215-0, Volume 10 [Issue 10], page 865, Type: http/URL
 

Development and pilot phase of a European MS register

Veröffentlicht: 2010 in Journal of Neurology; Volume 257 [Issue 10] S.1620-1627, doi:10.1007/s00415-010-5578-4, Type: http/URL
 

Symptomatology of MS: results from the German MS Registry

Veröffentlicht: 2009 in Journal of Neurology; Volume 256 [Issue 11] S.1932-1935, doi:10.1007/s00415-009-5257-5, Type: http/URL
 

National MS registries

Veröffentlicht: 2008 in Journal of Neurology, doi:10.1007/s00415-008-6019-5; Volume 255 [Suppl 6] S.102–108, Type: http/URL
 

Multiple-Sklerose-Register in Deutschland

Veröffentlicht: 15. Februar 2008 in Deutsches Ärzteblatt; Volume 105 [Issue 7] S.113-119, Type: http/URL
 

MS-Register in Deutschland: Abschließende Ergebnisse der Pilotphase

Veröffentlicht: 2007 in Neurol Rehabil; Volume 13 [Issue 4] S.193 – 200, Type: http/URL